Occam Places Dan Kemp as CEO of Shinobi Therapeutics
Shinobi Therapeutics, a newly formed iPS cell therapy company created through the merger of Thyas Ltd (Japan) and Evade Biotechnology (USA) has appointed Dan Kemp as CEO. Founded on the basis of highly innovative iPSC and immune evasion research out of the University of Kyoto and UCSF, the enterprise was funded by key investors including F-Prime Capital and Eight Roads.
Previously, Dan served as CEO of Wugen Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic, off-the-shelf cell therapies. Prior to Wugen, Dan held a variety of senior Business Development and R&D leadership roles with Takeda and Novartis.
Dan received his BSc and Ph.D. in molecular pharmacology from the University of Kent (UK).
Recent Placements
Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.